Collectively, chemical inhibitor and genetic mutant analyses indicate that cell surface CH60 directly recognizes HAPLN1-PTR1 and signals via a TLR4/MyD88/TRAF6 cascade to cause NF-κB activation in MM cells. Here, NFKB1 is linked to Miyoshi myopathy.